Ultragenyx Pharmaceutical Inc’s recent filing unveils that its Chief Financial Officer Horn Howard unloaded Company’s shares for reported $0.39 million on Oct 10 ’24. In the deal valued at $52.76 per share,7,465 shares were sold. As a result of this transaction, Horn Howard now holds 92,301 shares worth roughly $4.71 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, KAKKIS EMIL D sold 20,000 shares, generating $1,117,000 in total proceeds. Upon selling the shares at $55.85, the President & CEO now owns 2,223,985 shares.
Before that, Huizenga Theodore Alan sold 91 shares. Ultragenyx Pharmaceutical Inc shares valued at $5,113 were divested by the SVP, Chief Accounting Officer at a price of $56.19 per share. As a result of the transaction, Huizenga Theodore Alan now holds 41,551 shares, worth roughly $2.12 million.
Goldman upgraded its Ultragenyx Pharmaceutical Inc [RARE] rating to a Buy from a a Neutral in a research note published on June 06, 2024; the price target was increased to $67 from $56. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Wells Fargo began covering RARE with “an Overweight” recommendation on December 08, 2023.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock jump 0.14% to $51.06. Over the last five days, the stock has lost -3.79%. Ultragenyx Pharmaceutical Inc shares have risen nearly 6.78% since the year began. Nevertheless, the stocks have risen 39.51% over the past one year. While a 52-week high of $60.37 was reached on 09/16/24, a 52-week low of $34.06 was recorded on 06/18/24. SMA at 50 days reached $55.58, while 200 days put it at $47.90.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 50.02, which if violated will result in even more drops to 48.97. On the upside, there is a resistance level at 51.93. A further resistance level may holdings at 52.79. The Relative Strength Index (RSI) on the 14-day chart is 33.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.85, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.04%. Stochastics %K at 7.11% indicates the stock is a buying.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2024-10-15, dropping by -0.45 million shares to a total of 3.16 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 3.61 million shares. There was a decline of -14.21%, which implies that there is a negative sentiment for the stock.
